Crossmark Global Holdings, Inc. - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.

Quarter-by-quarter ownership
Crossmark Global Holdings, Inc. ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q1 2023$12
-68.4%
16,6140.0%0.00%
-100.0%
Q4 2022$38
-99.9%
16,6140.0%0.00%0.0%
Q3 2022$53,000
-15.9%
16,614
-1.1%
0.00%
-50.0%
Q2 2022$63,000
-39.4%
16,800
-13.5%
0.00%0.0%
Q1 2022$104,000
-59.7%
19,433
+1.9%
0.00%
-66.7%
Q4 2021$258,000
-14.0%
19,063
+14.0%
0.01%
-14.3%
Q3 2021$300,000
+5.3%
16,723
+0.7%
0.01%0.0%
Q2 2021$285,000
-7.2%
16,613
+8.3%
0.01%
-12.5%
Q1 2021$307,000
+18.5%
15,333
+0.7%
0.01%
+14.3%
Q4 2020$259,000
+3.6%
15,233
+0.9%
0.01%0.0%
Q3 2020$250,000
-28.0%
15,093
+0.7%
0.01%
-30.0%
Q2 2020$347,000
+38.8%
14,983
+7.2%
0.01%
+11.1%
Q1 2020$250,000
-20.6%
13,980
-4.2%
0.01%0.0%
Q4 2019$315,000
+29.1%
14,600
+9.1%
0.01%
+28.6%
Q3 2019$244,000
-51.9%
13,380
-6.1%
0.01%
-50.0%
Q2 2019$507,000
+8.3%
14,244
+2.2%
0.01%
+7.7%
Q1 2019$468,000
+4.5%
13,943
+2.2%
0.01%
-7.1%
Q4 2018$448,000
-58.5%
13,643
-22.9%
0.01%
-48.1%
Q3 2018$1,079,000
+24.7%
17,701
-0.1%
0.03%
+17.4%
Q2 2018$865,000
-41.6%
17,710
+27.0%
0.02%
-39.5%
Q1 2018$1,482,000
-17.8%
13,945
-53.8%
0.04%
-11.6%
Q4 2017$1,802,000
+156.0%
30,168
+2.8%
0.04%
+138.9%
Q3 2017$704,0000.0%29,3390.0%0.02%0.0%
Q3 2016$704,00029,3390.02%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q2 2020
NameSharesValueWeighting ↓
TIRSCHWELL & LOEWY INC 588,908$7,138,0001.23%
Granahan Investment Management 3,693,956$44,771,0001.21%
NEA Management Company, LLC 1,825,600$22,126,0001.09%
FIC CAPITAL INC 150,868$1,829,0000.75%
Rhenman & Partners Asset Management AB 181,797$2,203,0000.66%
SOPHROSYNE CAPITAL LLC 60,200$728,0000.64%
HARVEY CAPITAL MANAGEMENT INC 130,400$1,580,0000.63%
Artal Group S.A. 1,300,000$15,756,0000.57%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 564,418$6,840,0000.47%
OppenheimerFunds, Inc. 24,400,000$295,728,0000.35%
View complete list of NEKTAR THERAPEUTICS shareholders